Sarepta Therapeutics (SRPT) Posts Smaller-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sarepta Therapeutics (SRPT) PT Lowered to $168 at Piper Jaffray on 3Q Report; Lower Projected Enterprise Value Due to 'Eventual Cannibalization by DMD GeneRx'
October 25, 2018 7:54 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $168.00 (from $189.00) while maintaining a Overweight rating, following the company's third quarter earnings report.
Analyst Tenthoff notes a lowered outlook on SRPT shares on a "lower projected enterprise... More
Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
October 25, 2018 7:30 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $200.00) while maintaining a Outperform rating.
The analyst commented, "With Exondys 51 meeting expectations and the company continuing to execute on multiple clinical gene therapy and RNA development... More
